This Is Huge News for Eli Lilly Investors

The hottest area among healthcare investors right now revolves around advancements being made in weight loss. Known as glucagon-like peptide-1 (GLP-1) receptor agonists, blockbuster drugs such as Ozempic, Wegovy, Mounjaro, Zepbound, and others are completely redefining how care is provided to patients with diabetes or in need of weight management.While Danish-based pharmaceutical company Novo Nordisk (NYSE: NVO) leads the GLP-1 market (thanks in large part to enthusiasm for its pioneering Ozempic drug), its chief rival Eli Lilly (NYSE: LLY) is quickly gaining steam thanks to surging demand for its Mounjaro and Zepbound formulations.Here are some big moves Lilly is making to strengthen its position in the weight loss market. Knowing how Lilly is laying the groundwork for long-term sustained growth can help investors determine whether the stock is a good buy at the moment.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool